NCT00401544View on ClinicalTrials.gov

Darbepoetin Alfa With or Without Intravenous (IV) Iron

PHASE2CompletedINTERVENTIONAL

Enrollment

243

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

March 31, 2008

Conditions

AnemiaNon-Myeloid Malignancies

Interventions

DRUG

darbepoetin alfa

Darbepoetin alfa administered by subcutaneous injection.

DRUG

IV iron dextran

Administered by intravenous (IV) injection.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY